In vivo arrhythmogenicity of the marine biotoxin azaspiracid-2 in rats

Archives of Toxicology

Volumn 88, Issue 2, 2014, Pages 425-434

  Ferreiro, Sara F ^a   Vilariño, Natalia ^a   Carrera, Cristina ^a   Louzao, M Carmen ^a   Santamarina, Germán ^a   Cantalapiedra, Antonio G ^a   Rodríguez, Laura P ^a   Cifuentes, J Manuel ^a   Vieira, Andrés C ^a   Nicolaou, K C ^b,c   Frederick, Michael O ^b   Botana, Luis M ^a  

^a UNIVERSITY OF SANTIAGO DE COMPOSTELA   (Spain)

^b SCRIPPS RESEARCH INSTITUTE   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Azaspiracid; Cardiac biomarkers; Cardiotoxicity; ECG; hERG

Indexed keywords

ANIMALS; ARRHYTHMIAS, CARDIAC; BIOLOGICAL MARKERS; CHO CELLS; CRICETULUS; ELECTROCARDIOGRAPHY; ETHER-A-GO-GO POTASSIUM CHANNELS; FEMALE; FURANS; MYOCARDIUM; PATCH-CLAMP TECHNIQUES; POTASSIUM CHANNEL BLOCKERS; PYRANS; RATS; RATS, SPRAGUE-DAWLEY;

EID: 84893933186     PISSN: 03405761     EISSN: 14320738     Source Type: Journal    
DOI: 10.1007/s00204-013-1115-4     Document Type: Article

References (42)

1. Aasen JA, Espenes A et al (2010) Sub-lethal dosing of azaspiracid-1 in female NMRI mice. Toxicon 56(8):1419-1425
2. Alfonso A, Román Y et al (2005) Azaspiracid-4 inhibits Ca2+ entry by stored operated channels in human T lymphocytes. Biochem Pharmacol 69(11):1627-1636
3. Colman JR, Twiner MJ et al (2005) Teratogenic effects of azaspiracid-1 identified by microinjection of Japanese medaka (Oryzias latipes) embryos. Toxicon 45(7):881-890
4. EC (2004) Regulation (EC) No. 853/2004 of the European Parliament and of the Council of 29 April 2004 laying down specific hygiene rules for food animal origin. Off J Eur Commun L 134:55
5. EFSA (2008) Marine biotoxin in shellfish-azaspiracid group. Scientific opinion of the panel on contaminants in the food chain. EFSA J 723:1-52
6. EMEA (2005). ICH Topic S 7 B. The nonclinical evaluation of the potential for delayed ventricular repolarization (QT interval prolongation) by human pharmaceuticals. http://www.emea.europa.eu/pdfs/human/ich/042302en.pdf
7. Farraj AK, Hazari MS et al (2011) The utility of the small rodent electrocardiogram in toxicology. Toxicol Sci 121(1):11-30
8. Furey A, O'Doherty S et al (2010) Azaspiracid poisoning (AZP) toxins in shellfish: toxicological and health considerations. Toxicon 56(2):173-190
9. Gintant G (2011) An evaluation of hERG current assay performance: translating preclinical safety studies to clinical QT prolongation. Pharmacol Ther 129(2):109-119
10. Gintant GA, Su Z et al (2006) Utility of hERG assays as surrogate markers of delayed cardiac repolarization and QT safety. Toxicol Pathol 34(1):81-90
11. Guo L, Guthrie H (2005) Automated electrophysiology in the preclinical evaluation of drugs for potential QT prolongation. J Pharmacol Toxicol Methods 52(1):123-135
12. Guth BD (2007) Preclinical cardiovascular risk assessment in modern drug development. Toxicol Sci 97(1):4-20
13. Hancox JC, Levi AJ et al (1998) Time course and voltage dependence of expressed HERG current compared with native "rapid" delayed rectifier K current during the cardiac ventricular action potential. Pflugers Arch 436(6):843-853
14. Hancox JC, McPate MJ et al (2008) The hERG potassium channel and hERG screening for drug-induced torsades de pointes. Pharmacol Ther 119(2):118-132
15. Hoffmann P, Warner B (2006) Are hERG channel inhibition and QT interval prolongation all there is in drug-induced torsadogenesis? A review of emerging trends. J Pharmacol Toxicol Methods 53(2):87-105
16. Ito E, Satake M et al (2000) Multiple organ damage caused by a new toxin azaspiracid, isolated from mussels produced in Ireland. Toxicon 38(7):917-930
17. Ito E, Satake M et al (2002) Chronic effects in mice caused by oral administration of sublethal doses of azaspiracid, a new marine toxin isolated from mussels. Toxicon 40(2):193-203
18. James KJ, Fidalgo Saez MJ et al (2004) Azaspiracid poisoning, the food-borne illness associated with shellfish consumption. Food Addit Contam 21(9):879-892
19. Katchman AN, Koerner J et al (2006) Comparative evaluation of HERG currents and QT intervals following challenge with suspected torsadogenic and nontorsadogenic drugs. J Pharmacol Exp Ther 316(3):1098-1106
20. Keating MT, Sanguinetti MC (2001) Molecular and cellular mechanisms of cardiac arrhythmias. Cell 104(4):569-580
21. Kettenhofen R, Bohlen H (2008) Preclinical assessment of cardiac toxicity. Drug Discov Today 13(15-16):702-707
22. Kmecova J, Klimas J (2010) Heart rate correction of the QT duration in rats. Eur J Pharmacol 641(2-3):187-192
23. Lorsheyd A, de Lange DW et al (2005) PR and OTc interval prolongation on the electrocardiogram after binge drinking in healthy individuals. Neth J Med 63(2):59-63
24. McMahon T, Silke J (1996) Winter toxicity of unknown aetiology in mussels. Harmful Algae 14:2
25. Nicolaou KC, Frederick MO et al (2006) Second-generation total synthesis of azaspiracids-1, -2, and -3. Chem Asian J 1(1-2):245-263
26. O'Brien PJ (2008) Cardiac troponin is the most effective translational safety biomarker for myocardial injury in cardiotoxicity. Toxicology 245(3):206-218
27. Ofuji K, Satake M et al (1999) Two analogs of azaspiracid isolated from mussels, Mytilus edulis, involved in human intoxication in Ireland. Nat Toxins 7(3):99-102
28. Ozer J, Ratner M et al (2008) The current state of serum biomarkers of hepatotoxicity. Toxicology 245(3):194-205
29. Perry M, Sanguinetti M et al (2010) Revealing the structural basis of action of hERG potassium channel activators and blockers. J Physiol 588(Pt 17):3157-3167
30. Polak S, Wisniowska B et al (2009) Collation, assessment and analysis of literature in vitro data on hERG receptor blocking potency for subsequent modeling of drugs' cardiotoxic properties. J Appl Toxicol 29(3):183-206
31. Priest BT, Bell IM et al (2008) Role of hERG potassium channel assays in drug development. Channels (Austin) 2(2):87-93
32. Redfern WS, Carlsson L et al (2003) Relationships between preclinical cardiac electrophysiology, clinical QT interval prolongation and torsade de pointes for a broad range of drugs: evidence for a provisional safety margin in drug development. Cardiovasc Res 58(1):32-45
33. Sanguinetti MC, Jiang C et al (1995) A mechanistic link between an inherited and an acquired cardiac arrhythmia: HERG encodes the IKr potassium channel. Cell 81(2):299-307
34. Satake M, Ofuji K et al (1998) Azaspiracid, a new marine toxin having unique spiro ring assemblies, isolated from Irish mussels, Mytilus edulis. J Am Chem Soc 120(38):9967-9968
35. Shah RR (2005) Drug-induced QT interval prolongation-regulatory guidance and perspectives on hERG channel studies. Novartis Found Symp 266:251-280
36. Stummann TC, Beilmann M et al (2009) Report and recommendations of the workshop of the European centre for the validation of alternative methods for drug-induced cardiotoxicity. Cardiovasc Toxicol 9(3):107-125
37. Su Z, Limberis J et al (2009) Electrophysiologic characterization of a novel hERG channel activator. Biochem Pharmacol 77(8):1383-1390
38. Twiner MJ, Hess P et al (2005) Cytotoxic and cytoskeletal effects of azaspiracid-1 on mammalian cell lines. Toxicon 45(7):891-900
39. Twiner MJ, Doucette GJ et al (2012) Marine algal toxin azaspiracid is an open-state blocker of HERG potassium channels. Chem Res Toxicol 25(9):1975-1984
40. Vilariño N, Nicolaou KC et al (2007) Irreversible cytoskeletal disarrangement is independent of caspase activation during in vitro azaspiracid toxicity in human neuroblastoma cells. Biochem Pharmacol 74(2):327-335
41. Walker DB (2006) Serum chemical biomarkers of cardiac injury for nonclinical safety testing. Toxicol Pathol 34(1):94-104
42. Zeltser D, Justo D et al (2004) Drug-induced atrioventricular block: prognosis after discontinuation of the culprit drug. J Am Coll Cardiol 44(1):105-108